SOCIETY OF NEUROSCIENCE ANNUAL MEETING TO BE HELD 

November 11-15, 2023 Biolexis Therapeutics Scientific Team participates and present their pre-clinical stage small molecule HDAC6 inhibitor program for ALS indication at the “SfN” (Society of Neuroscience) Annual Meeting to be held on Nov 11-15, 2023 – Walter E....

14th Annual World Cancer Congress

July 22-24, 2023 Biolexis Therapeutics CSO invited to Chair Cancer Immunology & Immunotherapy session and present MolecuLern technology at 14th Annual World Cancer Congress – WCC 11: Cancer Immunology & Immunotherapy on July 22-24, 2023, at Barcelona, Spain....

Ai-Driven Drug Development Summit

April 26-27, 2023 Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at Ai-Driven Drug Development Summit Europe on April 26-27, 2023, in London. AI Driven Drug Development Summit Europe 2023 (aidrugdevelopmentsummiteu.com)